Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis
Andrea Crosignani, Pier Maria Battezzati, Walter Albisetti, Giuseppe Grandinetti, Luca Pietrogrande, Arianna Biffi, Massimo Zuin, Mauro Podda – 1 September 1994 – No satisfactory treatment is available for metabolic bone disease associated with primary biliary cirrhosis. On the basis of the similarities to postmenopausal osteoporosis, the rationale exists for calcitonin to be tested in clinical studies in patients with primary biliary cirrhosis—associated osteoporosis.